非酒精性脂肪肝与肠道菌群及益生菌的相关性研究进展  

Research progress on relationship between NAFLD and gut microbiota/probiotics

作　　者：王晓伟[1] 高鹏飞[1] 姚国强[1] 李晶[1] 刘乔[1] 胡殿庚 张和平[1] 

机构地区：[1]内蒙古农业大学乳品生物技术与工程教育部重点实验室,国家奶牛产业技术研发中心乳制品研究室,内蒙古呼和浩特010018

出　　处：《现代预防医学》2015年第12期2153-2155,2174,共4页Modern Preventive Medicine

基　　金：国家高技术研究发展计划(NO.2011AA100902);农业部现代农业产业技术体系建设项目(CARS-37)

摘　　要：非酒精性脂肪肝是一种代谢性疾病,其发病机制复杂。肠道菌群在非酒精性脂肪肝的发生及发展过程中起着重要的作用。而益生菌作为调节肠道菌群的有效手段,可以通过降低肠道内毒素水平,提高肠道黏膜屏障,减轻全身炎症反应等多种机制对非酒精性脂肪肝起到预防和改善作用。本文就近年来肠道菌群和非酒精性脂肪肝的相关性以及益生菌的调节作用作一综述,为今后的研究应用提供依据。NAFLD is a common chronic metabolic disease with complex pathogenesis. Gut microbiota plays an important role in the occurrence and development of the NAFLD. As an effective means to regulate gut microbiota, probiotics are living organisms that are primarily used in the prevention and alleviation of the NAFLD by reducing the gut endotoxin level, improving the intestinal mucosal barrier, relieving systemic inflammatory response and other mechanisms. In this review, the research advance about links between the gut microbiota and the NAFLD as well as the role of probiotics were discussed in recent years.

关 键 词：非酒精性脂肪肝 肠道菌群 益生菌 

分 类 号：R153[医药卫生—营养与食品卫生学]